Literature DB >> 32296968

Failure analysis of infection persistence after septic revision surgery: a checklist algorithm for risk factors in knee and hip arthroplasty.

Sofia Kilgus1, Daniel Karczewski2, Cindy Passkönig1, Tobias Winkler1, Doruk Akgün1, Carsten Perka1, Michael Müller1.   

Abstract

PURPOSE: Several studies describe risk factors for primary periprosthetic joint infection (PJI) and general treatment outcome factors like microbe spectrum or patient-specific risk factors. However, these general and patient dependent findings cannot solely explain all cases of infection persistence after a prior septic revision. This study analyzes possible specific and patient independent reasons for failure after revisions for PJI in knee and hip arthroplasty.
METHODS: In a prospective analysis all patients were included that were treated: (1) at our department, (2) with a two-stage exchange, (3) between 2013 and 2017, (4) due to an infection persistence after a previous revision for PJI. Possible reasons for infection persistence were identified using a checklist algorithm, based on international guidelines.
RESULTS: 70 patients with infection persistence could be included (44 knee joints, 26 hip joints). The average age was 71 years, the CCI (Charlson Comorbidity Index) 2.8 and the ASA (American Society of Anesthesiologists) score 2.7. In 85% at least one possible reason for patient independent infection persistence could be identified analyzing the previous infection therapy: (1) 50% inadequate therapy concept (n = 35), (2) 33% inadequate surgical debridement (n = 23), (3) 30% inadequate antimicrobial therapy (n = 21), (4) 13% missed external bacterial primary focus (n = 9). After the individual failure analysis, all 70 patients were treated with a two-stage exchange in our department and in 94.9% infection freedom could be achieved (34.3 ± 10.9 months follow-up).
CONCLUSIONS: In the majority of failed revisions with subsequent infection persistence at least one possible patient independent failure cause could be identified. The entire previous therapy should be critically reviewed following failing revisions to optimize the outcome of septic revisions. By using a checklist algorithm, high rates of infection freedom were achieved.

Entities:  

Keywords:  Arthroplasty; Checklist; Complications; Failure; Periprosthetic joint infection; Recurrent infection

Mesh:

Substances:

Year:  2020        PMID: 32296968     DOI: 10.1007/s00402-020-03444-0

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  3 in total

Review 1.  Revised histopathological consensus classification of joint implant related pathology.

Authors:  V Krenn; L Morawietz; G Perino; H Kienapfel; R Ascherl; G J Hassenpflug; M Thomsen; P Thomas; M Huber; D Kendoff; D Baumhoer; M G Krukemeyer; S Natu; F Boettner; J Zustin; B Kölbel; W Rüther; J P Kretzer; A Tiemann; A Trampuz; L Frommelt; R Tichilow; S Söder; S Müller; J Parvizi; U Illgner; T Gehrke
Journal:  Pathol Res Pract       Date:  2014-10-17       Impact factor: 3.250

2.  The Preoperative Microbial Detection is No Prerequisite for the Indication of Septic Revision in Cases of Suspected Periprosthetic Joint Infection.

Authors:  Daniel Karczewski; Tobias Winkler; Carsten Perka; Michael Müller
Journal:  Biomed Res Int       Date:  2018-06-21       Impact factor: 3.411

Review 3.  Management of Periprosthetic Joint Infection.

Authors:  Cheng Li; Nora Renz; Andrej Trampuz
Journal:  Hip Pelvis       Date:  2018-09-04
  3 in total
  2 in total

1.  Modular knee arthrodesis secures limb, mobility, improves quality of life, and leads to high infection control in periprosthetic knee infection, when revision knee arthroplasty is not an option.

Authors:  Y Gramlich; D Steinkohl; M Kremer; M Kemmerer; R Hoffmann; A Klug
Journal:  Arch Orthop Trauma Surg       Date:  2021-04-23       Impact factor: 3.067

2.  Failure Analysis in Multiple TKA Revisions-Periprosthetic Infections Remain Surgeons' Nemesis.

Authors:  Stephanie Kirschbaum; Sarah Erhart; Carsten Perka; Robert Hube; Kathi Thiele
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.